Introduction. Cardiovascular disease is a major cause of morbidity and mortality in hemodialysis patients. In addition to traditional cardiovascular risk factors, non-traditional cardiovascular risk factors such as inflammation were also involved. Reprocessed dialyzer has been showed to induce less inflammation than new dialyzer, but data in diacetate cellulose membrane have not been presented. Methods. Twenty hemodialysis (HD) patients were enrolled. Pre and post study design was conducted to know post dialysis concentration changes of interleukin 6 (IL-6), C-reactive protein (CRP) and soluble vascular cell adhesion molecule-1 (sVCAM-1) at reuse 0, 5 and 10. Patients were recruited if medically stable, on maintenance HD >3 months, using reprocessed diacetate cellulose membrane by automated machine with mixture of periacetic acid and hydrogen peroxide solution. Urea reduction ratio (URR) and delivered dialysis dose were used to evaluate dialysis adequacy at reuse 0, 5, and 10. Results. CRP concentration was decreased. Median concentration of CRP at reuse 0, 5 and 10 were 3.55 mg/L, 2.97 mg/L and 2.92 mg/L, p=0.074. There were no significant changes of IL-6 concentration. Median concentration of IL-6 at reuse 0, 5, and 10 were 9.05 pg/ml, 10.64 pg/ml and 8.51 pg/ml, p=0.316. Concentration of sVCAM-1 was not changed significantly, with mean sVCAM-1 concentration 3078±786 ng/ml, 3260±836 ng/ml and 3154±631 ng/ml at reuse 0, 5 and 10,p=0.746. During use of reprocessed dialyzer through 10 times, there were no significant changes of hemodialysis adequacy using URR and Kt/V.


1. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO study. Kidney Int. 2004;65(6):2380-9. 2. Sarnak MJ, Levey AS, Schoolwerth JC. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Council on Kidney in Cardiovascular Disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension. 2003;42(5):1050-65. 3. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340(2):115-26. 4. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant. 2001;16(Suppl 7):36-40. 5. Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? Neprol Dial Transplant. 2002;17(suppl 8):33-8. 6. Korevaar JC, Van Manen JG, Dekker FW, De Waart DR, Boeschoten EW, et al. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol. 2004;15(11):2916-22. 7. Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis. 2001;38(6):1343-50. 8. Bergstom J, Heimburger O, Lindholm B, Qureshi AR. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients. J Am Soc Nephrol. 1995;6:573. 9. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovaskuler risk and mortality in hemodialysis patients. Kidney Int. 1999;55(2):648-58. 10. Bonomini M, Heale M, Santarelli P, Stuard S, Settefrati N, et al. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron. 1998;79(4):399-407. 11. Mrowka C, Heintz B, Sieberth H-C. Is dialysis membrane responsible for increased circulating adhesion molecules during chronic haemodialysis? Clin Nephrol. 1999;52(5):312-21. 12. Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant. 2002;17(3):435-41. 13. Tolkars JI, Alter MJ, Arduino MJ. National surveillance of dialysisassociated diseases in the United States, 2000. Semin Dial. 2002;15(3):162-71. 14. Pereira BJG, Snodgrass B, Barber G, Perella C, Chopra S, et al. Cytokine production during in vitro hemodialysis with new and formaldehyde- or renalin-reprocessed cellulose dialyzers. J Am Soc Nephrol. 1995;6(4):1304-8. 15. Shaldon S. Dialyzer reuse: a practice that should be abandoned. Semin Dial. 1993;6:11-2. 16. Shaldon S. Reuse of hemodialyzers. Nephrol Dial Transplant. 1994;9:1226-7. 17. Qian JQ, Yu ZY, Dai HL, Huang PW, Zhang QY, et al. The study of IL-1β, TNF-α, IL-6 gene expression and plasma levels on hemodialysis before and after dialyzer reuse. Chinese Med J (Engl). 1997;110(7):508-11. 18. Teehan GS, Guo D, Perianayagam MC, Balakrishnan VS, Pereira BJG, et al. Reprocessed (High-Flux) Polyflux dialyzer resist transmembrane endotoxin passage and attenuate inflammatory markers. Blood Purif. 2004;22(4):329-37. 19. Pereira BJG, King AJ, Poutsiaka DD. Comparison of first use and reuse of cuprophan membranes on interleukin-1 receptor antagonist and interleukin-1 β production by blood mononuclear cells. Am J Kidney Dis. 1993;22(2):288-95. 20. Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, et al. Inflammatory signals associated with hemodialysis. Kidney Int. 2002;62(4):1408-16. 21. Tarakcioglu M, Erbagci AB, Usalan C, Deveci R, Kocabas R. Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediators Inflamm. 2003;12(1):15-9. 22. Girndt M, Heisel O, Kohler H. Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4 month long-term study. Nephrol Dial Transplant. 1999;14(3):676-82. 23. Gonzales C, Cava F, Ayllon A. Biological variation of interleukin1β, interleukin-8, and tumor necrosis factor-α in serum of healthy individuals. Clin Chem Lab Med. 2001;39(9):836-41. 24. Dugue B, Leppanen E. Short-term variability in the concentration of serum interleukin-6 and its soluble receptor in subjectively healthy persons. Clin Chem Lab Med. 1998;36(5):323-5. 25. Pereira BJG, King AJ, Poutsiaka DD. Comparison of first use and reuse of cuprophan membranes on interleukin-1 receptor antagonist and interleukin-1 β production by blood mononuclear cells. Am J Kidney Dis. 1993;22(2):288-95. 26. Tambunan M. Pemakaian dialiser proses ulang dan hasil yang diperoleh di RSUPN dr Cipto Mangunkusumo [Tesis]. Jakarta: Universitas Indonesia; 2004. 27. Murthy BVR, Pereira BJG. Effects of reuse on dialyzer function. Semin Dial. 2000;13(5):282-6. 28. Cheung AK, Agodoa LY, Daugirdas JT. Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group. J Am Soc Nephrol. 1999;10(1):117-27.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.